Skip to main content
SpringerLink
Log in

Systemic Therapy for Non-operable Colorectal Cancer Metastases

  • Chapter
  • First Online:
Liver Metastases

  • 911 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    *Recent studies have demonstrated the need for K-Ras evaluation prior to the use of EGFR directed therapies. Please see chapter 9 for more details.

References

  1. Saad ED, Hoff PM. Chemotherapy of metastatic colorectal cancer. Curr Treat Options Gastroenterol. 2005; 8(3): 239–247.

    Article  PubMed  Google Scholar 

  2. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001; 8(4): 347–53.

    Article  PubMed  CAS  Google Scholar 

  3. Heidelberger C, Chauhuri N, Dannenberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 1957; 179: 663–666.

    Article  PubMed  CAS  Google Scholar 

  4. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004; 22(18): 3766–75.

    Article  PubMed  CAS  Google Scholar 

  5. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol. 1998; 16(1): 301–8.

    Google Scholar 

  6. Aksoy S, Karaca B, Dincer M, Yalcin S. Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother. 2005; 39(3): 573–4.

    PubMed  Google Scholar 

  7. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul. 2001; 41: 151–7.

    Article  PubMed  CAS  Google Scholar 

  8. Volk J, Reinke F, van Kuilenburg AB, et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol. 2001; 12(4): 569–71.

    Article  PubMed  CAS  Google Scholar 

  9. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001; 19(8): 2282–92.

    PubMed  CAS  Google Scholar 

  10. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22(11): 2084–91.

    Article  PubMed  CAS  Google Scholar 

  11. Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005; 16(2): 282–8.

    Article  PubMed  CAS  Google Scholar 

  12. Pitot HC. US pivotal studies of irinotecan in colorectal carcinoma. Oncology. 1998; 12(8 Suppl 6): 48–53.

    PubMed  CAS  Google Scholar 

  13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13): 905–14.

    Article  PubMed  CAS  Google Scholar 

  14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229–37.

    Article  PubMed  CAS  Google Scholar 

  15. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001; 19(18): 3801–7.

    PubMed  CAS  Google Scholar 

  16. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24(13): 2065–72.

    Article  PubMed  CAS  Google Scholar 

  17. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16): 2938–47.

    PubMed  Google Scholar 

  18. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22(1): 23–30.

    Article  PubMed  CAS  Google Scholar 

  19. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999; 35(9): 1338–42.

    Article  PubMed  CAS  Google Scholar 

  20. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517): 495–7.

    Article  PubMed  CAS  Google Scholar 

  21. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc). 2003; 39 Suppl C: 1–16.

    CAS  Google Scholar 

  22. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol. 1998; 81(2): 105–15; quiz 115–6, 119.

    Article  PubMed  CAS  Google Scholar 

  23. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2): 145–7.

    Article  PubMed  CAS  Google Scholar 

  24. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5): 391–400.

    Article  PubMed  CAS  Google Scholar 

  25. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23(16): 3697–705. Epub 2005 Feb 28.

    Article  PubMed  CAS  Google Scholar 

  26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23): 2335–42.

    Article  PubMed  CAS  Google Scholar 

  27. Kopetz S, Glover K, Eng C, et al. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. J Clin Oncol. 2007; 25(18 s): 4089.

    Google Scholar 

  28. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12): 1539–44.

    Article  PubMed  CAS  Google Scholar 

  29. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / N016966, a randomized phase III trial in first-line metastatic colorectal cancer J Clin Oncol. 2007; 25(18 s): 4028.

    Google Scholar 

  30. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–45.

    Article  PubMed  CAS  Google Scholar 

  31. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23(9): 1803–10.

    Article  PubMed  CAS  Google Scholar 

  32. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol. 2007; 25(18 s): 4000.

    Google Scholar 

  33. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007; 18(1): 7–15.

    Article  PubMed  CAS  Google Scholar 

  34. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658–64.

    Article  PubMed  Google Scholar 

  35. Maindrault-Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004; 15(8): 1210–4.

    Article  PubMed  CAS  Google Scholar 

  36. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7): 1209–14.

    Article  PubMed  CAS  Google Scholar 

  37. Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000; 7(7): 490–5.

    Article  PubMed  CAS  Google Scholar 

  38. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999; 341(27): 2039–48.

    Article  PubMed  CAS  Google Scholar 

  39. Clancy TE, Dixon E, Perlis R, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg. 2005; 9(2): 198–206.

    Article  PubMed  Google Scholar 

  40. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005; 23(22): 4881–7.

    Article  PubMed  CAS  Google Scholar 

  41. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004; 240(6): 1052–61; discussion 1061–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Executive Director, Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil

    Paulo Marcelo G. Hoff

Authors
  1. Paulo Marcelo G. Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Kopetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

  2. São Paulo, Faculdade de Medicina da, Universidade de São Paulo,, Instituto do Cancer do Estado de, Ave Dr Arnaldo 251, São Paulo, 01246-000, São Paulo, Brazil

    Paulo M. Hoff

  3. University of Liverpool, St Helens Teach, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A. Audisio

  4. Center for Digestive Diseases, University Hospital Aintree, Lower Lane, Liverpool, L9 7AL, United Kingdom

    Graeme J. Poston

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London

About this chapter

Cite this chapter

Hoff, P.M.G., Kopetz, S. (2009). Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Vauthey, JN., Hoff, P., Audisio, R., Poston, G. (eds) Liver Metastases. Springer, London. https://doi.org/10.1007/978-1-84628-947-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-947-7_5

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-946-0

  • Online ISBN: 978-1-84628-947-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation